Changing lives through
innovation
SNAPSHOT
Building a track record of success
+
active product programs
M+
invested in innovation & product development
Research Sites
startups
revenue- driving agreements
What We Do
Virtici provides the leadership, space and funding support to transform innovations into products...
VALUE CREATION
-
1 Select
-
2 Innovate
-
3 Develop
Virtici leadership brings decades of experience
that intersect innovation and product development.
Virtici Ecosystem
Together we increase our reach and capital, resulting in enhanced innovation, cost-efficient product development, and more valuable medical products for patients.
Areas Of Innovation
Virtici is actively seeking the most innovative product and
platform concepts in the following disease areas.
-
Oncology
-
Microbiome
-
Neurology
-
Autoimmunity
-
Inflammation
-
Infectious Disease
The ASCEND Hub is a Regional Technology Accelerator Hub for the seven Western States: Alaska, Hawaii, Idaho, Montana, Nevada, New Mexico, and Wyoming. The NIH funded program empowers innovators to accelerate biomedical commercialization through entrepreneurial education, mentorship, and technology development funding.
Latest News
Rise Therapeutics Begins Operations of its GMP Manufacturing Facility
Rockville, MD. Rise Therapeutics announced today that they have successfully initiated operations of their GMP manufacturing facility based in Rockville, MD. Funding to help set up this GMP manufacturing operation came from the National Institute of Health (NIH) Commercialization Readiness Pilot (CRP) Program Grant, which assists small businesses with technical assistance and late-stage development projects that are not typically supported by SBIR and STTR Phase II and Phase IIB grants. Launching of operations for this facility was also supported by the financial contributions of the Montgomery County Economic Development Corporation.
Read more
Aclys Bio and Genmab Enter Research and Commercial License Option Agreement to Develop Proprietary Aclys Antibodies Against an Undisclosed Target
Aclys Bio Corp (“Aclys”), a company discovering and developing precision biologics for the treatment of cancer, earlier this month announced a new exclusive research and commercial license option agreement with Genmab A/S (Nasdaq: GMAB), an international biotech company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.
Read more
Rise Therapeutics Announces Publication of an Important Peer-Reviewed Journal Article Related to its R-3750 Program
Rockville, MD. Rise Therapeutics, a biotechnology company developing first-in-class targeted immunological-based biologics using a unique and proprietary oral delivery platform, announced today the publication of the co-authored article, “Lactococcus lactis Delivery of Surface Layer Protein A Protects Mice from Colitis by Re-Setting Host Immune Repertoire” in the journal Biomedicines.
Read more
Scioto Biosciences Doses First Patient in Autistic Disorder Study
Earlier this month, Scioto Biosciences, Inc. began their Phase Ib clinical trial of SB-121 for the treatment of Autistic DIsorder (AD).
Read morePrecision Medicine Leader Dennis H. Langer, M.D., J.D. Joins Javelin Oncology’s Board of Directors
Javelin Oncology, Inc. announced today that the company has named Dennis H. Langer, M.D., J.D. to the company’s board of directors as an independent director. Dr. Langer has served as a director of several public and private health care companies, and served in leadership roles in several pharmaceutical, biotechnology and diagnostic companies.
Read more
Celdara Medical Secures Funding to Develop an Adjuvanted Universal Flu Vaccine
Celdara Medical, LLC today announced that the National Institute of Allergy and Infectious Disease (NIAID) of the National Institutes of Health (NIH) has awarded a two-year Small Business Innovation Research (SBIR) contract to fund the development of the novel, parasite-derived, antigen-sparing protein adjuvant ASP-1 for flu vaccines.
Read more